Physician profile
Sandra M Tate
NPI 1326093493
$2,121.31
in general payments reported to CMS, 2019-2025
17 companies · $1,237 in 2025
The $1,237 reported for 2025 was more than what 88% of Psychiatric/Mental Health, Child & Adolescent (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $315).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $236 · 2022: $192 · 2023: $244 · 2024: $213 · 2025: $1,237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,693.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $345.94 | 2021-2025 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $279.20 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $273.44 | 2021-2025 | Caplyta |
| Alkermes, INC. | $264.22 | 2021-2025 | Aristada, Lybalvi |
| Corium, LLC | $247.30 | 2023-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $154.86 | 2025 | Austedo Xr, Uzedy |
| Abbvie INC. | $116.20 | 2023-2025 | |
| Ironshore Pharmaceuticals INC. | $112.32 | 2021-2024 | Jornay Pm |
| Neurocrine Biosciences, INC. | $70.84 | 2024-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $64.07 | 2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $59.18 | 2025 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $32.86 | 2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $31.04 | 2021 | |
| Axsome Therapeutics, INC. | $19.32 | 2025 | Auvelity |
| Lundbeck LLC | $18.70 | 2024 | Rexulti |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $18.51 | 2023 | Pediarix, Rotarix, Bexsero |
| Avanir Pharmaceuticals, INC. | $13.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Tate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.